Peloton has confidentially filed for an initial public offering in the US that would follow $995m of equity funding and provide exits for Comcast and Grace Beauty.

The WuXi Biologics, Eli Lilly and Alexandria Real Estate Equities-backed cancer therapy developer is targeting $74.7m in its IPO.

Having confidentially filed in late April, Karuna Therapeutics has publicly applied for an initial public offering that would raise $75m and provide exits to Nan Fung and PureTech Health.

Rocket Internet, Access Industries and Tengelmann-backed fashion e-commerce marketplace GFG could float in Germany next month.

The second-hand luxury goods marketplace has set down a $100m target for an initial public offering that would offer an exit for Novel TMT Ventures.

The immunotherapy technology developer has set a $230m target for an initial public offering that would offer exits to LabCorp, Illumina, Celgene and BD Biosciences.

Novo, GlaxoSmithKline, Pfizer, AbbVie, ShangPharma and Schrödinger are all in line for exits following the small-molecule drug developer's decision to file for an $86.3m initial public offering.

Alexandria Real Estate Equities-backed gene-edited seed developer Cibus has withdrawn its IPO application three months after setting a price range that would have raised $107m at the upper end.

Solid tumour treatment developer Atreca has set a $100m target for an initial public offering that will provide GlaxoSmithKline with an exit.

Personalis has filed to list on the Nasdaq Global Market through an offering that would come eight years after the genome sequencing platform was spun out of Stanford University.